Why Cancer Drug Resistance Matters
Resistance to oncology therapeutics—whether targeted therapy, immunotherapy, or chemotherapy—limits durable responses in patients. Understanding how tumors evolve under treatment pressure is critical to designing better next-line therapies and predictive biomarkers.
Crown Bioscience integrates resistance modeling across cell lines, PDXs, and patient-derived tools, coupled with biomarker and multiomics platforms, to help you anticipate, test, and overcome resistance before clinical failure.
Explore Multiple Solutions for Model Development
Our unique four-step approach offers personalized strategies to address various drug resistance challenges, facilitating the successful acceleration of your project. By analyzing intrinsic and acquired resistance across diverse therapeutic types and molecular targets, we craft tailored solutions that enhance treatment efficacy.
Developing New and Clinically Relevant Models
Navigate the complexities of drug resistance using our strategic solutions and robust resources, designed to accelerate your drug development journey and ensure you achieve success with greater efficiency.
Our customized integrated solutions provide you with a comprehensive suite of resistance models across in vitro, in vivo, ex vivo, and in silico platforms, supported by a living biobank of over 30 cancer types. Our ongoing R&D efforts continually expand our catalog, and we offer custom model development to meet specific research needs. By integrating biomarker strategies, we help predict clinical responses while enabling the identification of translatable solutions and accelerating research progress.
